Program
Semaglutide
Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.
Drug pageSemaglutide: every studyMany companies study it; this page follows only the 163 they lead. All 451 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 1518 open or running | phase 4since Jul 11, 2018 | Jun 11, 2008 | Dec 13, 2026phase 1 · NCT07225816 |
| CSPC Pharmaceutical Groupits history only | 20 open or running | phase 3since Nov 30, 2023 | Nov 30, 2023 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 21 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| Chengdu Brilliant Pharmaceuticalits history only | 11 open or running | phase 3since Mar 18, 2024 | Mar 18, 2024 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Gila Therapeuticsits history only | 11 open or running | phase 4since Apr 17, 2026 | Apr 17, 2026 | May 2027phase 4 · NCT07728383 |
| Korea United Pharm.its history only | 11 open or running | phase 1since Oct 28, 2026 | Oct 28, 2026 | Nov 1, 2027phase 1 · NCT07935200 |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Shanghai World Leader Pharmaceuticalits history only | 11 open or running | phase 1since Jan 28, 2026 | Jan 28, 2026 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Dec 13, 2024 | Dec 13, 2024 | none ahead |
| Vivani Medicalits history only | 11 open or running | phase 1since Feb 10, 2026 | Feb 10, 2026 | Dec 2026phase 1 · NCT07430059 |
Also a collaborator on its studies: Celerion and Avance Clinical Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 16, 2020.
- Aug 22, 2024Phase 4 study in ObesityNovo Nordisk · NCT06571383 · 500 enrolled · United States, Belgium, Canada and more
- Sep 12, 2024Phase 3 study in Weight ManagementCSPC Pharmaceutical Group · NCT06604624 · 462 enrolled · China
- Oct 7, 2024Phase 3 study in ObesityHangzhou Jiuyuan Gene Engineering · NCT06633783 · 370 planned · China
- Oct 13, 2024Phase 1 study in Healthy Volunteers Type 2 DiabetesNovo Nordisk · NCT06642584 · 90 enrolled · Canada
- Dec 13, 2024Sino Biopharmaceutical’s first study: phase 3 study in ObesityNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06738979 · 408 enrolled · China
- Nov 5, 2025Phase 1 study in ObesityNovo Nordisk · NCT07225816 · 71 planned · United States
- Nov 27, 2025Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT07271251 · 267 enrolled · Japan
- Jan 28, 2026Shanghai World Leader Pharmaceutical’s first study: phase 1 study in OverweightNew to Shanghai World Leader PharmaceuticalShanghai World Leader Pharmaceutical · NCT07465965 · 60 planned · United States
- Feb 10, 2026Vivani Medical’s first study: phase 1 study in ObesityNew to Vivani MedicalVivani Medical · NCT07430059 · 20 planned
- Apr 17, 2026Gila Therapeutics’ first study: phase 4 study in ObesityNew to Gila TherapeuticsGila Therapeutics · NCT07728383 · 40 planned · United States
- Aug 13, 2026Phase 3 study in OverweightNovo Nordisk · NCT07770841 · 450 planned · United States, Belgium, Bulgaria and more
- Sep 22, 2026Phase 1 study in ObesityNovo Nordisk · NCT07845578 · 60 planned · Austria
- Oct 21, 2026Phase 4 study in Renal Insufficiency, ChronicNovo Nordisk · NCT07900438 · 300 planned · China
- Oct 28, 2026Korea United Pharm.’s first study: phase 1 study in BioequivalenceNew to Korea United Pharm.Korea United Pharm. · NCT07935200 · 44 planned · South Korea
Ahead
- Dec 2026Primary completion: phase 1 study in ObesityVivani Medical · NCT07430059
- Dec 13, 2026Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07225816
- May 2027Primary completion: phase 4 study in ObesityGila Therapeutics · NCT07728383
- Sep 11, 2027Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07845578
TargetBeta
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
The newest 60 of 163 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07935200Bioequivalence · South Korea | 1 | Not yet recruiting | Korea United Pharm. | Nov 1, 2027 | 44 |
| NCT07900438Renal Insufficiency, Chronic · China | 4 | Recruiting | Novo Nordisk | Dec 20, 2029 | 300 |
| NCT07845578Obesity · Austria | 1 | Recruiting | Novo Nordisk | Sep 11, 2027 | 60 |
| NCT07770841Overweight · United States, Belgium, Bulgaria and more | 3 | Recruiting | Novo Nordisk | Feb 22, 2028 | 450 |
| NCT07728383Obesity · United States | 4 | Recruiting | Gila Therapeutics | May 2027 | 40 |
| NCT07430059Obesity | 1 | Not yet recruiting | Vivani Medical | Dec 2026 | 20 |
| NCT07465965Overweight · United States | 1 | Recruiting | Shanghai World Leader Pharmaceutical | Aug 21, 2026 | 60 |
| NCT07271251Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Novo Nordisk | Jun 29, 2026 | 267 |
| NCT07225816Obesity · United States | 1 | Recruiting | Novo Nordisk | Dec 13, 2026 | 71 |
| NCT06738979Obesity · China | 3 | Completed | Sino Biopharmaceutical | Mar 7, 2026 | 408 |
| NCT06642584Healthy Volunteers Type 2 Diabetes · Canada | 1 | Completed | Novo Nordisk | Jul 10, 2025 | 90 |
| NCT06633783Obesity · China | 3 | Not yet recruiting | Hangzhou Jiuyuan Gene Engineering | May 30, 2026 | 370 |
| NCT06604624Weight Management · China | 3 | Completed | CSPC Pharmaceutical Group | Aug 27, 2025 | 462 |
| NCT06571383Obesity · United States, Belgium, Canada and more | 4 | Active, not recruiting | Novo Nordisk | Nov 15, 2028 | 500 |
| NCT06497049Pharmacokinetics · Russian Federation | 1 | Completed | Geropharm | May 5, 2024 | 120 |
| NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more | 2 | Completed | Novo Nordisk | Nov 21, 2025 | 270 |
| NCT06339086Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Chengdu Brilliant Pharmaceutical | Aug 30, 2025 | 478 |
| NCT06267092Overweight · Germany | 1 | Completed | Novo Nordisk | Apr 7, 2025 | 164 |
| NCT06161844Diabetes Mellitus, Type 2 · China | 3 | Completed | CSPC Pharmaceutical Group | May 14, 2025 | 506 |
| NCT06097390Healthy Participants · Canada | 1 | Completed | Novo Nordisk | Feb 22, 2024 | 121 |
| NCT06083675Diabetes Mellitus, Type 2 · United States, Brazil, Bulgaria and more | 3 | Withdrawn | Novo Nordisk | Jan 24, 2025 | 0 |
| NCT06041217Overweight · China, Taiwan | 3 | Completed | Novo Nordisk | Apr 2, 2025 | 242 |
| NCT05996874Healthy Participants · Germany | 1 | Completed | Novo Nordisk | Apr 18, 2024 | 121 |
| NCT05950516Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Qilu Pharmaceutical | Nov 24, 2024 | 478 |
| NCT05891496Alzheimer Disease · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Aug 19, 2024 | 23 |
| NCT05890976Overweight · China | 3 | Completed | Novo Nordisk | Jan 16, 2025 | 200 |
| NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more | 3 | Completed | Novo Nordisk | Apr 14, 2025 | 148 |
| NCT05784402Healthy Participants · United States, Canada | 1 | Completed | Novo Nordisk | Feb 23, 2024 | 264 |
| NCT05816057Diabetes Mellitus, Type 2 · China | 3 | Completed | Hangzhou Jiuyuan Gene Engineering | Jul 25, 2023 | 476 |
| NCT05726227Obesity · United States, Austria, Belgium and more | 3 | Active, not recruiting | Novo Nordisk | Oct 15, 2025 | 212 |
| NCT05689099Diabetes Mellitus, Type 2 · United States | 1 | Completed | Novo Nordisk | May 30, 2023 | 20 |
| NCT05649137Obesity · United States, Bulgaria, Canada and more | 3 | Completed | Novo Nordisk | Oct 28, 2024 | 512 |
| NCT05646706Obesity · United States, Bulgaria, Canada and more | 3 | Completed | Novo Nordisk | Oct 30, 2024 | 1,407 |
| NCT05579249Obesity · United States | 4 | Completed | Novo Nordisk | Nov 27, 2024 | 500 |
| NCT05564117Overweight · United States, Canada, Germany and more | 3 | Completed | Novo Nordisk | Apr 18, 2024 | 307 |
| NCT05533632Diabetes Mellitus, Type 2 · Chile | 4 | Completed | Novo Nordisk | Jan 18, 2024 | 104 |
| NCT05514535Diabetes Mellitus, Type 2 · United States, Czechia, Greece and more | 3 | Completed | Novo Nordisk | Mar 5, 2025 | 573 |
| NCT05486065Diabetes Mellitus, Type 2 · United States, Greece, Hungary and more | 2 | Completed | Novo Nordisk | Oct 12, 2023 | 245 |
| NCT05478252Diabetes Mellitus, Type 2 · United States, Canada, Poland and more | 3 | Completed | Novo Nordisk | Aug 9, 2023 | 388 |
| NCT05444153Diabetes Mellitus, Type 2 | 3 | Withdrawn | Novo Nordisk | Oct 2, 2024 | 0 |
| NCT05429593Healthy Volunteers · Germany | 1 | Completed | Novo Nordisk | Mar 10, 2023 | 152 |
| NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Novo Nordisk | Mar 19, 2024 | 1,291 |
| NCT05227196Diabetes Mellitus, Type 2 · United States, Canada | 1 | Completed | Novo Nordisk | Jun 28, 2023 | 546 |
| NCT05232708Diabetes Mellitus · United Kingdom | 1 | Completed | Novo Nordisk | Aug 30, 2022 | 18 |
| NCT05132088Overweight · Japan, South Korea | 3 | Completed | Novo Nordisk | Jul 11, 2023 | 201 |
| NCT05064735Obesity · United States, Canada, Colombia and more | 3 | Completed | Novo Nordisk | Jul 24, 2023 | 407 |
| NCT05040971Obesity · Canada, Denmark, Finland and more | 3 | Completed | Novo Nordisk | Jan 6, 2023 | 207 |
| NCT05035095Obesity · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Mar 24, 2023 | 667 |
| NCT05035082Diabetes Mellitus, Type 2 · United States | 4 | Completed | Novo Nordisk | Jun 18, 2025 | 1,018 |
| NCT04998136Obesity · South Korea, Thailand | 3 | Completed | Novo Nordisk | Oct 16, 2023 | 150 |
| NCT04940078Obesity · Canada, Denmark | 1 | Completed | Novo Nordisk | Jan 19, 2022 | 40 |
| NCT04916470Diabetes Mellitus · United States, Argentina, Austria and more | 3 | Completed | Novo Nordisk | Oct 11, 2023 | 617 |
| NCT04865770Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Nov 21, 2024 | 106 |
| NCT04822181Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novo Nordisk | Apr 25, 2029 | 1,205 |
| NCT04817644Diabetes Mellitus, Type 2 · United States | 1 | Completed | Novo Nordisk | May 26, 2023 | 14 |
| NCT04788511Obesity · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Apr 18, 2023 | 529 |
| NCT04777409Early Alzheimer´s Disease · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Sep 15, 2025 | 1,840 |
| NCT04777396Alzheimer Disease · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Sep 16, 2025 | 1,840 |
| NCT04707469Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more | 3 | Completed | Novo Nordisk | Mar 7, 2023 | 1,606 |
| NCT04596631Diabetes Mellitus, Type 2 · United States, Australia, Austria and more | 3 | Completed | Novo Nordisk | Apr 29, 2025 | 132 |
How it is read
Names in the registry
- “semaglutide”, 83 entries
- “Semaglutide”, 66 entries
- “Oral semaglutide”, 11 entries
- “Semaglutide 2.4 mg”, 3 entries
- “Semaglutide J”, 3 entries
Codes read as this program: UI112, HD1916.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 94 studies
- Obesity, 42 studies
- Diabetes Mellitus, 17 studies
- Non-alcoholic Fatty Liver Disease, 4 studies
- Alzheimer Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.